Jefferson University Hospitals

Provider Profile

Daniel Silver, MD, PhD

Jefferson University Physician

Academic Title: Associate Professor
Director, Basic Science and Research in Medical Oncology
Leader, Breast Program, Sidney Kimmel Cancer Center

Medical Oncology
Medical Oncology - Breast Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340
1100 Walnut Street
3rd Floor
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-2230

Medical Services

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Fellow of the College of Physicians of Philadelphia 2016


  • University of California/San Francisco, Medical School


  • University of California, San Francisco


  • University of California, San Francisco


  • Dana Farber Cancer Institute

Recent Publications

MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy

BRCA1 pathway function in basal-like breast cancer cells

Mechanisms of BRCA1 tumor suppression

Mutational processes molding the genomes of 21 breast cancers

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

Chek2 DNA damage response pathway and inherited breast cancer risk

Poly ADP-ribose polymerase inhibitors: Science and current clinical development

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

Poly(ADP-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer

Efficacy of neoadjuvant cisplatin in triple-negative breast cancer

Complex landscapes of somatic rearrangement in human breast cancer genomes

Estrogen receptor-negative breast cancer: New insights into subclassification and targeting

Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells

Synthetic lethality - A new direction in cancer-drug development

Cancer: Crossing over to drug resistance

Further Evidence for BRCA1 Communication with the Inactive X Chromosome

Abnormalities of the inactive X chromosome are a common feature of brca1 mutant and sporadic basal-like breast cancer

Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

Association of BRCA1 with the inactive X chromosome and XIST RNA

HIN-1 and the nosology of breast cancer